Literature DB >> 31670453

Correlation between reflux burden, peristaltic function, and mucosal integrity in GERD patients.

Mentore Ribolsi1, Chandra Prakash Gyawali2, Edoardo Savarino3, Benjamin Rogers2, Arvind Rengarajan2, Marco Della Coletta3, Matteo Ghisa3, Michele Cicala1.   

Abstract

BACKGROUND: Mean nocturnal baseline impedance (MNBI) augments the diagnostic yield of multichannel intraluminal impedance-pH (MII-pH) monitoring. While acid exposure time (AET) correlates with MNBI, it remains unclear whether esophageal motility affects MNBI values. The present study was aimed at evaluating the respective roles of esophageal motor function and AET on MNBI.
METHODS: High-resolution manometry (HRM) studies and ambulatory 24-hour MII-pH monitoring tracings were retrospectively analyzed from consecutive endoscopy-negative GERD patients with typical symptoms responsive to previous acid-suppressive therapy from three tertiary care centers. Univariate and multivariate analyses were performed to determine predictors of pathologic MNBI values at 3 cm and 5 cm above the lower esophageal sphincter (LES). KEY
RESULTS: Patients with pathological AET displayed lower MNBI values at 3 cm and 5 cm (P < .01) compared to patients with non-pathological AET. Similarly, significantly lower MNBI values were also noted at both sites with type 3 EGJ compared to type 1 EGJ (P ≤ .02 for each comparison), and with absent contractility compared to normal peristalsis (P ≤ .02 for each comparison). On multivariate analysis, the presence of type 2 or 3 EGJ and absent contractility were associated with a significantly higher probability of pathological MNBI values at 3 cm and 5 cm above the LES. CONCLUSIONS AND INFERENCES: Disruption of the EGJ and absent contractility on HRM are both associated with lower MNBI values. HRM findings complement reflux testing using MII-pH monitoring.
© 2019 John Wiley & Sons Ltd.

Entities:  

Keywords:  GERD; esophagogastric junction; high-resolution manometry; mean nocturnal baseline impedance; pH-impedance monitoring

Year:  2019        PMID: 31670453     DOI: 10.1111/nmo.13752

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  6 in total

1.  Elimination of Dietary Triggers Is Successful in Treating Symptoms of Gastroesophageal Reflux Disease.

Authors:  Cesare Tosetti; Edoardo Savarino; Edoardo Benedetto; Rudi De Bastiani
Journal:  Dig Dis Sci       Date:  2020-06-24       Impact factor: 3.199

2.  Impact of esophageal mucosal permeability markers on provocation-induced esophageal reflexes in high-risk infants.

Authors:  Sudarshan R Jadcherla; Roseanna Helmick; Kathryn A Hasenstab; Minna Njeh; Enas Alshaikh
Journal:  Physiol Rep       Date:  2022-06

3.  Value of adjunctive evidence from MII-pH monitoring and high-resolution manometry in inconclusive GERD patients with AET 4-6.

Authors:  Ya Jiang; Liuqin Jiang; Bixing Ye; Lin Lin
Journal:  Therap Adv Gastroenterol       Date:  2021-05-30       Impact factor: 4.409

4.  Role of the Mean Nocturnal Baseline Impedance in Identifying Evidence Against Pathologic Reflux in Patients With Refractory Gastroesophageal Reflux Disease Symptoms as Classified by the Lyon Consensus.

Authors:  Yanhong Wu; Zihao Guo; Chuan Zhang; Yutao Zhan
Journal:  J Neurogastroenterol Motil       Date:  2022-01-30       Impact factor: 4.924

5.  Correlation between gastroesophageal flap valve abnormality and novel parameters in patients with gastroesophageal reflux disease symptoms by the lyon consensus.

Authors:  Zihao Guo; Yanhong Wu; Yutao Zhan; Chuan Zhang
Journal:  Sci Rep       Date:  2021-07-23       Impact factor: 4.379

6.  Patients With Definite and Inconclusive Evidence of Reflux According to Lyon Consensus Display Similar Motility and Esophagogastric Junction Characteristics.

Authors:  Mentore Ribolsi; Edoardo Savarino; Benjamin Rogers; Arvind Rengarajan; Marco Della Coletta; Matteo Ghisa; Michele Cicala; C Prakash Gyawali
Journal:  J Neurogastroenterol Motil       Date:  2021-10-30       Impact factor: 4.924

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.